- $120.95m
- $107.23m
- $2.04m
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary
Humacyte Q2 net loss widens on inventory, production costs
Brief: Humacyte Q2 Operating Expenses USD 27.402 Million
Humacyte Inc expected to post a loss of 10 cents a share - Earnings Preview
Humacyte Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Humacyte Announces FDA Acceptance Of Ind For First-In-Human Clinical Study Of Ctev For Coronary Artery Bypass Grafting
U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte
Brief: Humacyte, Inc. Announces Proposed Public Offering Of Common Stock
Brief: Humacyte Atev Met Superiority Primary Endpoint Compared To Standard Of Care Av Fistula In Interim Analysis Of V012 Phase 3 Study In Female Dialysis Access Patients
Brief: Humacyte Announces Symvess® Is Now Under Contract With The Strategic Acquisition Center (Sac) Of The U.S. Department Of Veterans Affairs
Brief: Humacyte Appoints Dr. Todd E. Rasmussen As Chief Surgical Officer
Humacyte posts bigger-than-expected Q4 loss
Brief: Humacyte Q4 Basic EPS USD -0.13